Developer docs
API playgroundTry for free, no card

Search company profiles

AQEMIA

Full company profile

uuid0000eqg

Namestring
AQEMIA
Legal namestring
AQEMIA
Websiteurl
aqemia.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

AQEMIA is a Paris-based TechBio company founded in 2019 that operates a proprietary drug-discovery platform called QEMI (Quantum-Enhanced Molecular Invention), which fuses fast physics algorithms derived from quantum mechanics with generative AI to design novel small-molecule drug candidates. The platform's defining technical claim is physics-level prediction accuracy at up to 10,000× the speed of conventional physics-based methods, and—unlike most AI-drug-discovery competitors—it does not require experimental training data, enabling design of molecules against novel or undruggable targets. The platform was built on 12+ years of academic research at CNRS, École Normale Supérieure, Oxford, and Cambridge, supported by 40+ peer-reviewed publications, and is the product's primary technical moat.

The company's go-to-market is enterprise field sales targeting large pharmaceutical companies via multi-year strategic co-development partnerships involving upfront payments, research funding, and milestone payments. Flagship customers include Sanofi ($140-150M multi-year collaboration spanning oncology, immunology, inflammation, and neurology), Servier (immuno-oncology, since 2021), Janssen (pilot, since 2022), and Novalix (epitranscriptomics, since 2025). AQEMIA simultaneously pursues a wholly/partly owned proprietary pipeline—placing candidates into biotech spin-offs for clinical development—and secures non-dilutive funding through initiatives such as the France 2030 grant program (€7M / $7.4M for RNA therapeutics, April 2025).

AQEMIA is privately held, headquartered in Paris (1 Boulevard Pasteur) with a London office opened in early 2025, employs approximately 70 people, and has raised more than $100M cumulatively across pre-seed, multi-tranche Series A, and a late-2024 growth round led by Cathay Innovation. Pricing is not publicly disclosed; revenue mechanics rest on milestone-laden pharma collaborations, grants, and the future licensing or acquisition value of internally generated drug candidates.

Short descriptiontext

AQEMIA is a Paris-based TechBio company whose QEMI platform combines quantum physics and generative AI to design novel drug candidates without experimental data, partnering with large pharmaceutical firms through multi-year, milestone-based co-development agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, generative AI pharma, physics-based molecular design, computational drug discovery, TechBio platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Pharmaceutical Partnerships
TypeSubscription Recurring
Description

Multi-year collaboration agreements with pharmaceutical companies involving upfront payments, research funding, and milestone payments. Includes co-development of drug candidates with revenue sharing or full ownership transferred upon milestones.

businesswire.com
2Grant Funding
TypeSubscription Recurring
Description

Non-dilutive funding from government initiatives such as France 2030 for specific research programs including RNA therapeutics and epitranscriptomics.

aqemia.com
3Proprietary Drug Pipeline
TypeLicensing Royalties
Description

Wholly or partly owned drug candidates placed into constellation of biotech spin-offs to carry out clinical trials, with potential licensing or acquisition value.

labiotech.eu
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

AQEMIA operates a proprietary platform called QEMI that combines fast quantum-physics algorithms with generative AI to design novel drug candidates without relying on experimental training data. The platform predicts drug-target affinities at atomic scale up to 10,000x faster than conventional methods, enabling the discovery of small molecules for previously undruggable targets. The company monetizes this capability through multi-year co-development partnerships with large pharmaceutical firms and through its own proprietary pipeline of wholly or partly owned drug programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Physics-level accuracy up to 10,000× faster than conventional methods
+2 more records
Product overview1 text field

AQEMIA operates as a TechBio company offering a single unified technology platform, QEMI (Quantum-Enhanced Molecular Invention), which combines fast physics derived from quantum mechanics with generative AI. The platform enables physics-first drug discovery without experimental training data, supporting both wholly owned therapeutic programs and partnered collaborations with pharmaceutical companies. AQEMIA's approach is applied across oncology, immunology, inflammation, neurological diseases, and RNA therapeutics, with programs progressing toward clinical trials.

Product and service3 records
1QEMI Platform
CategoryAI Drug Discovery Platform
Description

Proprietary generative AI and fast-physics platform that combines quantum-mechanics-based predictions with generative AI to design novel molecules. QEMI delivers physics-level accuracy up to 10,000x faster than conventional methods, enabling scalable exploration of chemical space for drug discovery, and is used by AQEMIA to support both partnered programs and its wholly owned pipeline.

2Pharmaceutical Co-Discovery Partnerships
CategoryDrug Discovery Collaboration Services
Description

Multi-year collaboration agreements under which AQEMIA applies the QEMI platform to design novel molecules for pharmaceutical partners' therapeutic programs, in exchange for upfront payments, research funding, and milestone-based economics. Customers include Sanofi, Servier, and Janssen (Johnson & Johnson).

3Proprietary Drug Pipeline
CategoryProprietary Therapeutic Pipeline
Description

Wholly or partly owned drug candidates discovered via the QEMI platform, advanced through biotech spin-offs or licensing arrangements toward clinical milestones. Includes a recent RNA Therapeutics Expansion Program supported by France 2030 grant funding for epitranscriptomics and small-molecule RNA targeting including anti-cancer projects.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Partnership for epitranscriptomics programs advancing small-molecule RNA targeting for diseases including cancer treatments.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-12-05
Description

Major multi-year collaboration valued at $150 million for AI and quantum physics-driven drug discovery across multiple therapeutic areas including oncology, immunology, inflammation, and neurological diseases. Original announcement in December 2023, with ongoing programs advancing toward clinical trials.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-14
Description

Pilot study to evaluate and utilize Aqemia's physics-driven drug discovery technology for potential drug development programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-03
Description

AI and quantum physics-driven drug discovery collaboration focused on immuno-oncology. Extended first collaboration in June 2022 for additional oncology programs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven small-molecule drug discovery company using convolutional neural networks for structure-based design. Comparable to AQEMIA on AI-physics hybrid discovery and pharma partnerships, with a broader portfolio of industry collaborations.

2Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company spun out of DeepMind, applying AlphaFold-derived methods to pharma discovery. Direct competitor on AI-for-drug-discovery with substantially greater capital backing and access to Google's compute infrastructure.

TypeDirect peer
Description

AI-driven drug discovery company combining generative AI, deep learning, and reinforcement learning for de novo molecule design and target identification. Direct competitor to AQEMIA's QEMI platform with overlapping therapeutic-area focus and several clinical-stage assets already in the pipeline.

TypeBroad incumbent
Description

AI-driven drug discovery company using knowledge graphs and machine learning for target identification and molecule design. Comparable on AI-augmented pharma discovery but with a more target-identification-led approach than AQEMIA's physics-based molecular design.

TypeDirect peer
Description

AI- and quantum-physics-driven drug discovery company combining computational chemistry with experimental validation. Comparable to AQEMIA's physics-first methodology and crystal-structure prediction capabilities; larger scale with extensive CRO presence in China.

TypeDirect peer
Description

Physics-based computational drug discovery platform combining molecular simulation, machine learning, and collaborative pharma partnerships. Closely comparable to AQEMIA on the physics-first methodology and enterprise pharma BD model; Schrödinger is publicly listed with a more mature product portfolio.

TypeDirect peer
Description

AI-driven precision medicine company using generative AI and active learning to accelerate small-molecule drug discovery. Direct competitor on platform model and big-pharma partnerships; Exscientia has advanced multiple candidates into clinical trials.

TypeRegional player
Description

France-based AI company specializing in generative modeling for small-molecule drug design. Direct overlap on AI-driven molecular generation and a regional peer in the French TechBio ecosystem, though focused exclusively on generative chemistry rather than physics-based affinity prediction.

TypeDirect peer
Description

Publicly listed TechBio combining high-throughput biology with AI/ML to discover and develop drugs at scale. Directly comparable to AQEMIA on platform-driven discovery model and pharma partnership strategy, though Recursion operates at a much larger scale with multiple clinical programs.

TypeEmerging player
Description

AI-driven drug discovery company combining physics-based modeling with generative AI for small-molecule design. Strong technical overlap with AQEMIA's physics-first QEMI platform and a similar stage of company development, making it a closely comparable emerging peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AQEMIA

AI Drug Discovery Platformaqemia.com

AQEMIA is a Paris-based TechBio company whose QEMI platform combines quantum physics and generative AI to design novel drug candidates without experimental data, partnering with large pharmaceutical firms through multi-year, milestone-based co-development agreements.

What AQEMIA does

AQEMIA is a Paris-based TechBio company founded in 2019 that operates a proprietary drug-discovery platform called QEMI (Quantum-Enhanced Molecular Invention), which fuses fast physics algorithms derived from quantum mechanics with generative AI to design novel small-molecule drug candidates. The platform's defining technical claim is physics-level prediction accuracy at up to 10,000× the speed of conventional physics-based methods, and—unlike most AI-drug-discovery competitors—it does not require experimental training data, enabling design of molecules against novel or undruggable targets. The platform was built on 12+ years of academic research at CNRS, École Normale Supérieure, Oxford, and Cambridge, supported by 40+ peer-reviewed publications, and is the product's primary technical moat.

The company's go-to-market is enterprise field sales targeting large pharmaceutical companies via multi-year strategic co-development partnerships involving upfront payments, research funding, and milestone payments. Flagship customers include Sanofi ($140-150M multi-year collaboration spanning oncology, immunology, inflammation, and neurology), Servier (immuno-oncology, since 2021), Janssen (pilot, since 2022), and Novalix (epitranscriptomics, since 2025). AQEMIA simultaneously pursues a wholly/partly owned proprietary pipeline—placing candidates into biotech spin-offs for clinical development—and secures non-dilutive funding through initiatives such as the France 2030 grant program (€7M / $7.4M for RNA therapeutics, April 2025).

AQEMIA is privately held, headquartered in Paris (1 Boulevard Pasteur) with a London office opened in early 2025, employs approximately 70 people, and has raised more than $100M cumulatively across pre-seed, multi-tranche Series A, and a late-2024 growth round led by Cathay Innovation. Pricing is not publicly disclosed; revenue mechanics rest on milestone-laden pharma collaborations, grants, and the future licensing or acquisition value of internally generated drug candidates.

AQEMIA firmographics

Firmographics
Name
AQEMIA
Legal name
AQEMIA
Website
https://aqemia.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
AQEMIA is a Paris-based TechBio company whose QEMI platform combines quantum physics and generative AI to design novel drug candidates without experimental data, partnering with large pharmaceutical firms through multi-year, milestone-based co-development agreements.
Ownership category
akta.pro rank

AQEMIA industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • AI drug discovery
  • Generative AI pharma
  • Physics-based molecular design
  • Computational drug discovery
  • TechBio platform

Where AQEMIA is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

AQEMIA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Strategic Pharmaceutical Partnerships: Multi-year collaboration agreements with pharmaceutical companies involving upfront payments, research funding, and milestone payments. Includes co-development of drug candidates with revenue sharing or full ownership transferred upon milestones.
  2. Grant Funding: Non-dilutive funding from government initiatives such as France 2030 for specific research programs including RNA therapeutics and epitranscriptomics.
  3. Proprietary Drug Pipeline: Wholly or partly owned drug candidates placed into constellation of biotech spin-offs to carry out clinical trials, with potential licensing or acquisition value.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

AQEMIA product offering

Product offering

Core offering

AQEMIA operates a proprietary platform called QEMI that combines fast quantum-physics algorithms with generative AI to design novel drug candidates without relying on experimental training data. The platform predicts drug-target affinities at atomic scale up to 10,000x faster than conventional methods, enabling the discovery of small molecules for previously undruggable targets. The company monetizes this capability through multi-year co-development partnerships with large pharmaceutical firms and through its own proprietary pipeline of wholly or partly owned drug programs.

Product overview

AQEMIA operates as a TechBio company offering a single unified technology platform, QEMI (Quantum-Enhanced Molecular Invention), which combines fast physics derived from quantum mechanics with generative AI. The platform enables physics-first drug discovery without experimental training data, supporting both wholly owned therapeutic programs and partnered collaborations with pharmaceutical companies. AQEMIA's approach is applied across oncology, immunology, inflammation, neurological diseases, and RNA therapeutics, with programs progressing toward clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • QEMI Platform Proprietary generative AI and fast-physics platform that combines quantum-mechanics-based predictions with generative AI to design novel molecules. QEMI delivers physics-level accuracy up to 10,000x faster than conventional methods, enabling scalable exploration of chemical space for drug discovery, and is used by AQEMIA to support both partnered programs and its wholly owned pipeline.
  • Pharmaceutical Co-Discovery Partnerships Multi-year collaboration agreements under which AQEMIA applies the QEMI platform to design novel molecules for pharmaceutical partners' therapeutic programs, in exchange for upfront payments, research funding, and milestone-based economics. Customers include Sanofi, Servier, and Janssen (Johnson & Johnson).
  • Proprietary Drug Pipeline Wholly or partly owned drug candidates discovered via the QEMI platform, advanced through biotech spin-offs or licensing arrangements toward clinical milestones. Includes a recent RNA Therapeutics Expansion Program supported by France 2030 grant funding for epitranscriptomics and small-molecule RNA targeting including anti-cancer projects.

Quantifiable outcome

  • Physics-level accuracy up to 10,000× faster than conventional methods
  • +2 more outcomes

Companies that use AQEMIA

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

AQEMIA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

AQEMIA partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor, flagship and core.

  • NovalixminorStrategic or Co-development Partner · 1 April 2025Partnership for epitranscriptomics programs advancing small-molecule RNA targeting for diseases including cancer treatments.
  • SanofiflagshipStrategic or Co-development Partner · 5 December 2023Major multi-year collaboration valued at $150 million for AI and quantum physics-driven drug discovery across multiple therapeutic areas including oncology, immunology, inflammation, and neurological diseases. Original announcement in December 2023, with ongoing programs advancing toward clinical trials.
  • Janssen (Johnson & Johnson)minorStrategic or Co-development Partner · 14 February 2022Pilot study to evaluate and utilize Aqemia's physics-driven drug discovery technology for potential drug development programs.
  • ServiercoreStrategic or Co-development Partner · 3 December 2021AI and quantum physics-driven drug discovery collaboration focused on immuno-oncology. Extended first collaboration in June 2022 for additional oncology programs.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

AQEMIA competitors and assessment

Company assessment

Direct peers

  • Atomwise: AI-driven small-molecule drug discovery company using convolutional neural networks for structure-based design. Comparable to AQEMIA on AI-physics hybrid discovery and pharma partnerships, with a broader portfolio of industry collaborations.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind, applying AlphaFold-derived methods to pharma discovery. Direct competitor on AI-for-drug-discovery with substantially greater capital backing and access to Google's compute infrastructure.
  • Insilico Medicine: AI-driven drug discovery company combining generative AI, deep learning, and reinforcement learning for de novo molecule design and target identification. Direct competitor to AQEMIA's QEMI platform with overlapping therapeutic-area focus and several clinical-stage assets already in the pipeline.
  • XtalPi: AI- and quantum-physics-driven drug discovery company combining computational chemistry with experimental validation. Comparable to AQEMIA's physics-first methodology and crystal-structure prediction capabilities; larger scale with extensive CRO presence in China.
  • Schrödinger: Physics-based computational drug discovery platform combining molecular simulation, machine learning, and collaborative pharma partnerships. Closely comparable to AQEMIA on the physics-first methodology and enterprise pharma BD model; Schrödinger is publicly listed with a more mature product portfolio.
  • Exscientia: AI-driven precision medicine company using generative AI and active learning to accelerate small-molecule drug discovery. Direct competitor on platform model and big-pharma partnerships; Exscientia has advanced multiple candidates into clinical trials.
  • Recursion Pharmaceuticals: Publicly listed TechBio combining high-throughput biology with AI/ML to discover and develop drugs at scale. Directly comparable to AQEMIA on platform-driven discovery model and pharma partnership strategy, though Recursion operates at a much larger scale with multiple clinical programs.

Broad incumbents

  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning for target identification and molecule design. Comparable on AI-augmented pharma discovery but with a more target-identification-led approach than AQEMIA's physics-based molecular design.

Regional players

  • Iktos: France-based AI company specializing in generative modeling for small-molecule drug design. Direct overlap on AI-driven molecular generation and a regional peer in the French TechBio ecosystem, though focused exclusively on generative chemistry rather than physics-based affinity prediction.

Emerging players

  • Iambic: AI-driven drug discovery company combining physics-based modeling with generative AI for small-molecule design. Strong technical overlap with AQEMIA's physics-first QEMI platform and a similar stage of company development, making it a closely comparable emerging peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

AQEMIA social profiles

Digital presence

AQEMIA compliance and trust

Trust signal

Compliance1 record

AQEMIA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AQEMIA leadership team

Management profile

Number of profiles

Profiles2 records

AQEMIA funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AQEMIA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AQEMIA

What does AQEMIA do?

AQEMIA operates a proprietary platform called QEMI that combines fast quantum-physics algorithms with generative AI to design novel drug candidates without relying on experimental training data. The platform predicts drug-target affinities at atomic scale up to 10,000x faster than conventional methods, enabling the discovery of small molecules for previously undruggable targets. The company monetizes this capability through multi-year co-development partnerships with large pharmaceutical firms and through its own proprietary pipeline of wholly or partly owned drug programs.

Is AQEMIA a public or private company?

AQEMIA is a private company. It is classified as venture growth investor backed and is currently operating.

When was AQEMIA founded?

AQEMIA was founded in 2019. It employs 51 to 100 people.

Where is AQEMIA based?

AQEMIA is headquartered in Paris, France, in the Europe region.

How does AQEMIA make money?

Three revenue lines are on record. Strategic Pharmaceutical Partnerships are the primary driver. The others are grant Funding and proprietary Drug Pipeline.

Who are AQEMIA's main competitors?

Direct peers on record are Atomwise, Isomorphic Labs, Insilico Medicine, XtalPi, Schrödinger, Exscientia and Recursion Pharmaceuticals. BenevolentAI is listed as a broad incumbent. Iktos is listed as a regional player. Iambic is listed as an emerging player.

Does AQEMIA have an API?

No public API is recorded for AQEMIA.

What industry is AQEMIA in?

AQEMIA's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AllsciAqemia Expands Sanofi AI Drug Discovery DealAqemia and Sanofi have expanded their multi-year AI drug discovery collaboration, with a new therapeutic target nominated under the partnership originally struck in December 2023. The expansion makes Aqemia eligible for up to USD 140 million in aggregate upfront and milestone payments across all programs in the deal. The collaboration uses Aqemia's Qemi physics-based generative AI platform, with research teams in Paris and London designing candidate molecules against targets nominated by Sanofi scientists in Boston, Frankfurt and Paris.MarketScreenerAqemia and Sanofi Expand Research CollaborationSanofi has expanded its multi-year research collaboration with Aqemia by nominating a new therapeutic target, triggering a milestone payment and extending the scope of work between the two companies. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to $140 million in total upfront and milestone payments across programs. The partnership leverages Aqemia's proprietary physics-based generative AI platform (Qemi) for drug discovery, with collaboration spanning researchers across Paris, London, Boston, and Frankfurt.FinancialContent Business PageAqemia and Sanofi Expand Their Research CollaborationAqemia announced the expansion of its multi-year research collaboration with Sanofi, marked by the nomination of a new therapeutic target and a milestone payment. The collaboration, first announced in December 2023 with up to $140 million in potential upfront and milestone payments, spans drug discovery from initial hit identification through development candidate selection. The partnership now operates across multiple continents with researchers in Paris, London, Boston, and Frankfurt working jointly on Sanofi's targets, including challenging first-in-class projects.AETOSWireAqemia and Sanofi Expand Their Research CollaborationAqemia and Sanofi expanded their multi-year research collaboration by nominating a new therapeutic target and triggering a milestone payment. The partnership, first announced in December 2023, makes Aqemia eligible for up to $140 million in upfront and milestone payments across programs.MorningstarAqemia and Sanofi Expand Their Research CollaborationAqemia and Sanofi expanded their research collaboration by nominating a new therapeutic target and triggering a milestone payment. The partnership, first announced in December 2023, makes Aqemia eligible for up to $140 million in upfront and milestone payments. The collaboration spans drug discovery from initial hits to development candidate selection.FRENCHWEB.FRNEXT40 2026 : qui sont les nouveaux champions de la souveraineté technologique française ?The Next40 2026 selection prioritizes strategic technologies like quantum computing, AI, and batteries, with 40% of companies from deeptech. The criteria now include technological excellence and contribution to economic challenges, marking a shift from growth-focused to industrial policy.Maddyness“Cap sur le Royaume-Uni” : entrepreneurs et investisseurs partagent leurs conseils pour réussir outre-MancheA four-part podcast series by Maddyness and the UK Embassy in France features French entrepreneurs and investors sharing advice on entering the UK market. They highlight the UK's mature market, talent pool, and regulatory environment as key advantages, while emphasizing the need for local adaptation and proof of results.The Pharma LetterAqemia’s differentiated discovery platform creates ‘bright future ahead’Aqemia is gaining recognition from big pharma for its innovative discovery platform in the pharmaceutical and biotech industry. The article highlights industry updates, clinical trials, mergers and acquisitions, legal and regulatory issues, and executive appointments within the sector.MaddynessHealthtech, biotech: why the UK is emerging as an essential hubFrench AI drug discovery startup Aqemia opened a London office in early 2025 following a $38 million fundraising round at the end of 2024, and now employs 15 people in the UK out of a total workforce of 70, citing access to specialized talent and a mature life sciences ecosystem as primary drivers. The United Kingdom has set ambitious targets to become Europe's leading life sciences hub by 2030 and the world's third-largest economy by 2035, supported by over £2 billion in public funding, competitive tax incentives including 20% R&D credits and 10% patent box rates, and significant regulatory reforms to clinical trials. Major pharmaceutical companies including Merck (£1 billion investment at King's Cross) and Moderna (Oxfordshire mRNA facility) have already established significant operations in the UK, while the government has launched the most significant clinical trial regulation reform in 20 years.